DENA0004010

Shine was founded in 2010 with the goal of becoming the world leader in the safe, clean, affordable production of medical isotopes. Since 2010, Shine has aggressively pursued the establishment of a domestic source of high specific activity Mo-99 without the use of HEU to end the chronic shortages US patients are experiencing.

Shine Technologies

THE OVERALL PROJECT GOAL IS TO ESTABLISH RELIABLE, HIGH-VOLUME, COMMERCIAL PRODUCTION OF MEDICAL ISOTOPES IN THE US AND TO PROVIDE A LONG-TERM SOLUTION FOR DOMESTIC NEEDS OF MOLYBDENUM-99 (MO-99) WITHOUT THE USE OF HIGHLY ENRICHED URANIUM (HEU). THE COMPLETION OF THIS PROJECT WILL ENSURE A STABLE COMMERCIAL SUPPLY OF THE DAUGHTER ISOTOPE OF MO-99, TECHNETIUM-99M (TC-99M), THE MOST IMPORTANT RADIOISOTOPE IN NUCLEAR MEDICINE, AND A PRIMARY DIAGNOSTIC TOOL IN THE DETECTION OF HEART DISEASE AND CANCER WHILE REDUCING THE THREAT OF NUCLEAR PROLIFERATION. AS AN ADDITIONAL BENEFIT, THE PROCESS WILL PRODUCE OTHER MEDICAL ISOTOPES RESULTING FROM FISSION, INCLUDING IODINE-131 (I-131) AND XENON-133 (XE-133), AND WILL BE CAPABLE OF PRODUCING MANY NEUTRON-CAPTURE BASED ISOTOPES AS WELL. THE PROJECT WILL BUILD AND COMMERCIALIZE AN ACCELERATOR-DRIVEN, LOW ENRICHED URANIUM (LEU) PRODUCTION TECHNOLOGY THAT WILL MEET MORE THAN HALF OF THE US DEMAND FOR MO-99, PRODUCING AT LEAST 1,500 6-DAY CI OF MO 99 PER WEEK WITHOUT THE USE OF HEU. THIS MO-99 WILL CONFORM TO EXISTING INDUSTRY SPECIFICATIONS AND WILL BE DISTRIBUTED THROUGH COMMERCIAL PARTNERS USING EXISTING INFRASTRUCTURE.

81.009 - Molybdenum-99 Program

National Nuclear Security Administration (NNSA) [DOE]

Nuclear Non-Proliferation Funds [DOE - NNSA]

Rock County, Wisconsin United States

City-Wide

Commercial Domestic Production of Moly-99 without the Use of Highly Enriched Uranium (DE-FOA-0002303)

Amendment Since initial award the End Date has been extended from 10/21/24 to 10/21/26 and the total obligations have increased 556% from $70,000,000 to $459,091,682.